Log in

Relevant bibliographies by topics / Anti-breast cancer drug / Journal articles

To see the other types of publications on this topic, follow the link: Anti-breast cancer drug.

Journal articles on the topic 'Anti-breast cancer drug'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anti-breast cancer drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Lou, Song. "Multifunctional Nanotherapeutics for Drug-Resistant Breast Cancer." Bioequivalence & Bioavailability International Journal 6, no. 1 (2022): 1–6. http://dx.doi.org/10.23880/beba-16000160.

Full text

Abstract:

Tumors are inherently resilient and always develop drug-resistance, leading to poor patient therapy effect. With the developing of sophisticated analytical tools, some novel strategy on improving targeting of anti-cancer delivery is developed to better thwart drug-resistance. This report demonstrates a multilayered nano-system to serve as a multifunctional platform for the treatment of drug-resistant breast cancers. This nano-system is composed of a poly (lactic-co-glycolic acid) core, a liposome second layer, and a hyaluronic acid outmost layer. The different types of drug, loaded in differen

APA, Harvard, Vancouver, ISO, and other styles

2

Hussain, Tanveer, Seeram Ramakrishna, and Sharjeel Abid. "Nanofibrous drug delivery systems for breast cancer: a review." Nanotechnology 33, no. 10 (2021): 102001. http://dx.doi.org/10.1088/1361-6528/ac385c.

Full text

Abstract:

Abstract Breast cancer is the most common type of cancer among women. Breast-conserving surgery (BCS) is one of the preferred approaches for treating non-invasive or early-stage breast cancers. However, local-regional recurrence (LRR) is one of the critical risk factors after BCS. As many as 10%–20% of BCS cases may show LRR within 5 years and almost 50% within 10 years after surgery. Radiation therapy is one of the preferred treatments used to prevent LRR after BCS. However, because of possible side-effects of radiation therapy, targeted drug delivery systems (DDS) based on nanofibers loaded

APA, Harvard, Vancouver, ISO, and other styles

3

Cai, Alvan, Yuan Chen, Lily S. Wang, John K. Cusick, and Yihui Shi. "Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer." Cancers 16, no. 15 (2024): 2635. http://dx.doi.org/10.3390/cancers16152635.

Full text

Abstract:

HER2 (human epidermal growth factor receptor 2) is highly expressed in a variety of cancers, including breast, lung, gastric, and pancreatic cancers. Its amplification is linked to poor clinical outcomes. At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strategies. An impressive body of FDA-approved drugs, including anti-HER2 monoclonal antibodies (mAbs), antibody–drug conjugates

APA, Harvard, Vancouver, ISO, and other styles

4

Bernatsky, S., R. Ramsey-Goldman, M. Petri, et al. "Breast cancer in systemic lupus." Lupus 26, no. 3 (2016): 311–15. http://dx.doi.org/10.1177/0961203316664595.

Full text

Abstract:

Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE durat

APA, Harvard, Vancouver, ISO, and other styles

5

Ton Tai, Dinh Xuan, Le Thi Huong, Tran Hoang Mai, Vu Manh Hung, Nguyen Thi Huyen, and Bui Thanh Tung. "Screening in silico the human epidermal growth factor receptor-2inhibitory effect of isoflavones by molecular docking method for their potential use in breast cancer." Ministry of Science and Technology, Vietnam 65, no. 2 (2023): 47–53. http://dx.doi.org/10.31276/vjste.65(2).47-53.

Full text

Abstract:

Isoflavones are secondary phenolic metabolites found in most legumes. These compounds have important pharmacological significance such as anti-osteoporosis, anti-aging, and anti-cancer properties. Breast cancer is one of the most common cancers in women worldwide. Human epidermal growth factor receptor-2 (HER2) is an important target in breast cancer treatment. In this study, we evaluated the ability of sixty isoflavones compounds to inhibit the HER2 enzyme for their potential use in breast cancer treatments by the molecular docking method. Molecular docking was done by Autodock vina software.

APA, Harvard, Vancouver, ISO, and other styles

6

Samuel, Samson, Elizabeth Varghese, Peter Kubatka, Chris Triggle, and Dietrich Büsselberg. "Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer." Biomolecules 9, no. 12 (2019): 846. http://dx.doi.org/10.3390/biom9120846.

Full text

Abstract:

Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incid

APA, Harvard, Vancouver, ISO, and other styles

7

Li, Jiaying, Guowei Zhang, and Hongxia Yang. "Optimal modeling of anti breast cancer drug candidates." Highlights in Science, Engineering and Technology 45 (April 18, 2023): 350–60. http://dx.doi.org/10.54097/hset.v45i.7573.

Full text

Abstract:

As breast cancer is one of the most common cancers with high mortality rate in the world, this paper studies the optimal screening of anti-breast cancer candidate drugs. First, the data of 729 compound molecular descriptors are preprocessed, rough cleaned and filtered to 253, and then the cluster feature tree and correlation analysis are used to further reduce the dimension of data redundancy information, and 29 representative molecular descriptors are screened. In order to determine the importance and significance variables affecting the activity of compounds, the preliminary results were obt

APA, Harvard, Vancouver, ISO, and other styles

8

Zhang, Ya-Zhou, Hai-Lin Liu, Qian-Song He, and Zhi Xu. "The In Vitro Anticancer Activity and Potential Mechanism of Action of 1-[(1R,2S)-2-fluorocyclopropyl]Ciprofloxacin-(4-methyl/phenyl/benzyl-3- aryl)-1,2,4-triazole-5(4H)-thione Hybrids." Current Topics in Medicinal Chemistry 20, no. 16 (2020): 1493–98. http://dx.doi.org/10.2174/1568026620666200310123723.

Full text

Abstract:

Aims: Development of 1-[(1R, 2S)-2-fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)- thione hybrids as potential dual-acting mechanism anticancer agent to overcome the drug resistance. Background: Chemotherapy is an essential tool for the treatment of lung and female breast cancers, and numerous anticancer agents have been launched for this purpose. However, the clinical outcomes of chemotherapy are usually far from satisfactory due to the side effects and resistance to chemotherapeutic drugs. Thus, it is urgent to develop novel anti-lung and anti-breast cancer agents. Background: Chemothe

APA, Harvard, Vancouver, ISO, and other styles

9

Rajagopal, Kalirajan, Anandarajagopal Kalusalingam, Anubhav Raj Bharathidasan, et al. "In Silico Drug Design of Anti-Breast Cancer Agents." Molecules 28, no. 10 (2023): 4175. http://dx.doi.org/10.3390/molecules28104175.

Full text

Abstract:

Cancer is a condition marked by abnormal cell proliferation that has the potential to invade or indicate other health issues. Human beings are affected by more than 100 different types of cancer. Some cancer promotes rapid cell proliferation, whereas others cause cells to divide and develop more slowly. Some cancers, such as leukemia, produce visible tumors, while others, such as breast cancer, do not. In this work, in silico investigations were carried out to investigate the binding mechanisms of four major analogs, which are marine sesquiterpene, sesquiterpene lactone, heteroaromatic chalcon

APA, Harvard, Vancouver, ISO, and other styles

10

Cao, Yi, Yunjin Li, Ruijie Liu, Jianhua Zhou, and Kuansong Wang. "Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer." Cancers 15, no. 9 (2023): 2568. http://dx.doi.org/10.3390/cancers15092568.

Full text

Abstract:

The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15–30% of breast cancers. In HER2-positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental

APA, Harvard, Vancouver, ISO, and other styles

11

Bernard, Philip S., Whitney Wooderchak-Donahue, Mei Wei, et al. "Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer." Cancers 13, no. 6 (2021): 1219. http://dx.doi.org/10.3390/cancers13061219.

Full text

Abstract:

Patients with breast cancer often receive many drugs to manage the cancer, side effects associated with cancer treatment, and co-morbidities (i.e., polypharmacy). Drug–drug and drug–gene interactions contribute to the risk of adverse events (AEs), which could lead to non-adherence and reduced efficacy. Here we investigated several well-characterized inherited (germline) pharmacogenetic (PGx) targets in 225 patients with breast cancer. All relevant clinical, pharmaceutical, and PGx diplotype data were aggregated into a single unifying informatics platform to enable an exploratory analysis of th

APA, Harvard, Vancouver, ISO, and other styles

12

Serini, Simona, Roberta Cassano, Federica Curcio, Sonia Trombino, and Gabriella Calviello. "Nutraceutical-Based Nanoformulations for Breast and Ovarian Cancer Treatment." International Journal of Molecular Sciences 23, no. 19 (2022): 12032. http://dx.doi.org/10.3390/ijms231912032.

Full text

Abstract:

Different strategies have been investigated for a more satisfactory treatment of advanced breast cancer, including the adjuvant use of omega-3 polyunsaturated fatty acids (PUFAs). These nutritional compounds have been shown to possess potent anti-inflammatory and antiangiogenic activities, the capacity to affect transduction pathways/receptors involved in cell growth and to reprogram tumor microenvironment. Omega-3 PUFA-containing nanoformulations designed for drug delivery in breast cancer were shown to potentiate the effects of enclosed drugs, enhance drug delivery to target sites, and minim

APA, Harvard, Vancouver, ISO, and other styles

13

Martin, Miguel, and Sara López-Tarruella. "Emerging Therapeutic Options for HER2-Positive Breast Cancer." American Society of Clinical Oncology Educational Book, no. 36 (May 2016): e64-e70. http://dx.doi.org/10.1200/edbk_159167.

Full text

Abstract:

The natural history of HER2-positive breast cancer has progressively improved since the introduction of the first anti-HER2 directed therapy (trastuzumab). Trastuzumab has significantly increased survival of patients with HER2-positive metastatic breast cancer and, after the standardization of the use of this drug in the adjuvant setting in 2005, has also avoided many disease recurrences and, consequently, saved many lives. Later on, the introduction of lapatinib offered new choices for patients with advanced HER2-positive breast cancer, although the drug has failed to show a clear efficacy in

APA, Harvard, Vancouver, ISO, and other styles

14

Kashyap, Dharambir, Shalmoli Bhattacharya, Santosh Irinike, et al. "Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study." Breast Disease 43, no. 1 (2024): 25–36. http://dx.doi.org/10.3233/bd-230011.

Full text

Abstract:

BACKGROUND: Tumour microenvironment (TME) contributes to resistance to anti-cancer drugs through multiple mechanisms including secretion of pro-survival factors by cancer associated fibroblasts (CAFs). In this study, we determined the chemotherapy resistance producing potential of CAFs in molecular subtypes of breast cancer. METHODS: The CAFs were isolated from fresh lumpectomy/mastectomy specimens of different molecular subtypes of breast cancer. The CAFs were cultured and secretome was collected from each breast cancer subtype. Breast cancer cell lines MCF-7, SK-BR3, MDA-MB-231, and MDA-MB-4

APA, Harvard, Vancouver, ISO, and other styles

15

Sun, Xiatian. "Optimized Modeling of Anti-Breast Cancer Drug Candidates." International Journal of Computer Science and Information Technology 3, no. 2 (2024): 167–78. http://dx.doi.org/10.62051/ijcsit.v3n2.19.

Full text

Abstract:

Breast cancer is often referred to as the "Pink Killer", and its incidence rate ranks first among female malignant tumors. It has been found that the expression of estrogen receptors alpha (ERα) plays a very important role in breast lesions, and compounds that can antagonize the activity of ERα may be candidates for the treatment of breast cancer. In this paper, it is of practical significance to construct a quantitative structure-activity relationship (QSAR) model of compounds to screen potential compounds that can antagonize the activity of ERα by using a machine learning approach, and to co

APA, Harvard, Vancouver, ISO, and other styles

16

胥, 阳. "Optimal Modeling of Anti-breast Cancer Drug Candidate." Modeling and Simulation 11, no. 01 (2022): 28–39. http://dx.doi.org/10.12677/mos.2022.111003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Seongmo, Kang, Suehyun Lee, Hyunah Shin, and Hyun Uk Kim. "Abstract 3157: Prediction of adverse drug reactions of anti-breast cancer drugs using machine learning." Cancer Research 83, no. 7_Supplement (2023): 3157. http://dx.doi.org/10.1158/1538-7445.am2023-3157.

Full text

Abstract:

Abstract Chemotherapy is a representative treatment option for cancers, but one of the challenges during the course of cancer treatment is the possible occurrence of adverse drug reactions (ADRs) caused by an anticancer drug. For example, ADRs such as encephalopathy, radiation recall dermatitis, acute cardiogenic shock and febrile neutropenia have been reported for 5-fluorouracil, an anticancer drug used to treat several cancer types. These ADRs may be caused by a single drug or by interactions with other drugs. Unfortunately, it is extremely difficult to predict potential ADRs a priori becaus

APA, Harvard, Vancouver, ISO, and other styles

18

Cocco, Stefania, Alessandra Leone, Michela Piezzo, et al. "Targeting Autophagy in Breast Cancer." International Journal of Molecular Sciences 21, no. 21 (2020): 7836. http://dx.doi.org/10.3390/ijms21217836.

Full text

Abstract:

Breast cancer is a heterogeneous disease consisting of different biological subtypes, with differences in terms of incidence, response to diverse treatments, risk of disease progression, and sites of metastases. In the last years, several molecular targets have emerged and new drugs, targeting PI3K/Akt/mTOR and cyclinD/CDK/pRb pathways and tumor microenvironment have been integrated into clinical practice. However, it is clear now that breast cancer is able to develop resistance to these drugs and the identification of the underlying molecular mechanisms is paramount to drive further drug deve

APA, Harvard, Vancouver, ISO, and other styles

19

Nagayama, Aiko, Neelima Vidula, Leif Ellisen, and Aditya Bardia. "Novel antibody–drug conjugates for triple negative breast cancer." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592091598. http://dx.doi.org/10.1177/1758835920915980.

Full text

Abstract:

Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application o

APA, Harvard, Vancouver, ISO, and other styles

20

Singh, Atamjit, Karanvir Singh, Kamaljit Kaur, et al. "Coumarin as an Elite Scaffold in Anti-Breast Cancer Drug Development: Design Strategies, Mechanistic Insights, and Structure–Activity Relationships." Biomedicines 12, no. 6 (2024): 1192. http://dx.doi.org/10.3390/biomedicines12061192.

Full text

Abstract:

Breast cancer is the most common cancer among women. Currently, it poses a significant threat to the healthcare system due to the emerging resistance and toxicity of available drug candidates in clinical practice, thus generating an urgent need for the development of new potent and safer anti-breast cancer drug candidates. Coumarin (chromone-2-one) is an elite ring system widely distributed among natural products and possesses a broad range of pharmacological properties. The unique distribution and pharmacological efficacy of coumarins attract natural product hunters, resulting in the identifi

APA, Harvard, Vancouver, ISO, and other styles

21

Guo, Hua, and Quan-Ping Diao. "The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds." Current Topics in Medicinal Chemistry 20, no. 16 (2020): 1499–503. http://dx.doi.org/10.2174/1568026620666200310124416.

Full text

Abstract:

Aims: To develop novel anti-breast cancer agents and discuss the structure-activity relationship of bis-isatin scaffolds. Background: Breast cancer is the most common invasive cancer and the second leading cause of cancer death in women after lung cancer. Bis-isatin scaffolds possess potential anti-breast cancer activity, and some of them such as Indirubin could induce cancer cells apoptosis via multiply mechanisms. Objective: The primary objective of this study was to evaluate the potential of bis-isatin scaffolds with alkyl/ether linkers between the two isatin moieties against different huma

APA, Harvard, Vancouver, ISO, and other styles

22

Mehta, Sandhya, Jinlin Song, Melissa Pavilack, et al. "Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients." Journal of Clinical Oncology 38, no. 29_suppl (2020): 282. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.282.

Full text

Abstract:

282 Background: HER2-positive (+) metastatic breast cancer (mBC) has a poor prognosis and many patients require multiple lines of HER2 targeted regimens. This study aims to examine the treatment sequencing of anti-HER2 regimens for HER2+ mBC among Medicare beneficiaries. Methods: A retrospective study was conducted using linked 1999-2016 Surveillance, Epidemiology, and End Results (SEER) cancer registries and Medicare claims. Adults patients who had mBC diagnosis, HER2+ status documented in SEER or claims of ≥1 anti-HER2 drug, continuous enrollment in Medicare from the date of mBC diagnosis un

APA, Harvard, Vancouver, ISO, and other styles

23

Maloba, Geofrey Ouma, Tom Were, Erick Barasa, Nasreldeen Mohamed, Arshi Arshi, and Ferenc Gallyas. "Synergistic Effects of 2-Deoxyglucose and Diclofenac Sodium on Breast Cancer Cells: A Comparative Evaluation of MDA-231 and MCF7 Cells." International Journal of Molecular Sciences 26, no. 10 (2025): 4894. https://doi.org/10.3390/ijms26104894.

Full text

Abstract:

Resistance of breast cancers to chemotherapy remains a global challenge to date. Drug combination studies between anti-cancer agents are increasingly becoming therapeutic strategies, geared towards alleviating breast cancers. Previously, 2-deoxyglucose has been shown to target and interrupt glycolysis. Available evidence also suggests that diclofenac, which was originally designed as a pain reliever, could inhibit the proliferation of breast cancer cells. However, the reverse Warburg effect and other metabolic reprogramming mechanisms in breast cancers limit the pharmacological application of

APA, Harvard, Vancouver, ISO, and other styles

24

Ahtit, Mustapha, Soulaymani Abdelmajid, Khadmaoui Abderrazak, R. Benkirane, Soulaymani Bencheikh Rachida, and E. Kerak. "Les Effets Indésirables Digestifs De La Chimiothérapie : Cas Des Patients De L’institut National D’oncologie De Rabat (Maroc)." European Scientific Journal, ESJ 12, no. 33 (2016): 454. http://dx.doi.org/10.19044/esj.2016.v12n33p454.

Full text

Abstract:

An adverse reaction of an anticancer drug is a harmful and an unintended reaction by patient suffering from cancer disease who is often polymedicated. The treatment of cancers by anti-cancer molecules produces serious adverse drug effects. The main purpose of this paper is to present and evaluate the digestive adverse effects involved in anti-cancer drugs and their potential of correlation to anticipate, prevent and improve the quality of care of patient suffering from cancer disease. This is a prospective study that that enrolled 147 patients seen between January 25 and June 25, 2009 with adv

APA, Harvard, Vancouver, ISO, and other styles

25

Samy, B. Gopal, S. Karthika Devi, and J. Priya Dharshini. "MOLECULAR DOCKING OF BREAST CANCER RECEPTORS AGAINST ANTI-CANCER DRUG SOLASODINE." Applied Biological Research 26, no. 1 (2024): 58–65. http://dx.doi.org/10.48165/abr.2024.26.01.8.

Full text

Abstract:

Cancer is a deadly disease that occurs in skin, pancreas, breast, and other body parts. Breast cancer is nowadays more common and can develop from various cell lines like MCF-7, MDA-MB-231, BT-20, etc. Early diagnosis and treatment can reduce the frequency of fatalities due to breast cancer, but early cancer screenings are often postponed due to erroneous information, fear, and ignorance. In the present work, we used molecular docking to find out the effect of solasodine binding on different cancer receptors. Solasodine was extracted from black nightshade (Solanum nigrum), a weed that was long

APA, Harvard, Vancouver, ISO, and other styles

26

Ahmad Shariff, Siti Hajar, Wan Khartini Wan Abdul Khodir, Shafida Abd Hamid, Muhammad Salahuddin Haris, and Mohamad Wafiuddin Ismail. "Poly(Caprolactone)-b-Poly(Ethylene Glycol)-Based Polymeric Micelles as Drug Carriers for Efficient Breast Cancer Therapy: A Systematic Review." Polymers 14, no. 22 (2022): 4847. http://dx.doi.org/10.3390/polym14224847.

Full text

Abstract:

Recently, drug delivery systems based on nanoparticles for cancer treatment have become the centre of attention for researchers to design and fabricate drug carriers for anti-cancer drugs due to the lack of tumour-targeting activity in conventional pharmaceuticals. Poly(caprolactone)-b-poly(ethylene glycol) (PCL-PEG)-based micelles have attracted significant attention as a potential drug carrier intended for human use. Since their first discovery, the Food and Drug Administration (FDA)-approved polymers have been studied extensively for various biomedical applications, specifically cancer ther

APA, Harvard, Vancouver, ISO, and other styles

27

Najjar, Mariana K., Sara G. Manore, Angelina T. Regua, and Hui-Wen Lo. "Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer." Genes 13, no. 11 (2022): 2065. http://dx.doi.org/10.3390/genes13112065.

Full text

Abstract:

Human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is overexpressed in 20–30% of breast cancers and is associated with poor prognosis and worse overall patient survival. Most women with HER2-positive breast cancer receive neoadjuvant chemotherapy plus HER2-targeted therapies. The development of HER2-directed therapeutics is an important advancement in targeting invasive breast cancer. Despite the efficacy of anti-HER2 monoclonal antibodies, they are still being combined with adjuvant chemotherapy to improve overall patient outcomes. Recently, significant progress has been

APA, Harvard, Vancouver, ISO, and other styles

28

Zhang, Yuzhu, Huachao Li, Hongyan Zhang та ін. "A small molecule LN435a targeting TGFβR1 exerts promising antitumor effects on breast cancer." Journal of Clinical Oncology 39, № 15_suppl (2021): e15069-e15069. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15069.

Full text

Abstract:

e15069 Background: Breast cancer has overtaken lung cancer as the most diagnosed cancer. Despite conventional treatment, metastases occur in 20-30% of patients, resulting in death. This study aims to screen of effective drugs by metastatic patient-derived organoid and the potential molecular mechanism. Methods: Breast Cancer patient-derived organoid (PDO) model was established from the patient who have multiple drug resistance, multiple visceral and contralateral breast metastases. The organoid morphologies was tested by hematoxylin-eosin (HE) staining and immunohistochemistry (IHC). Then, pha

APA, Harvard, Vancouver, ISO, and other styles

29

Zhu, Runqi, Tianqun Lang, Qi Yin, and Yaping Li. "Nano drug delivery systems improve metastatic breast cancer therapy." Medical Review 1, no. 2 (2021): 244–74. http://dx.doi.org/10.1515/mr-2021-0011.

Full text

Abstract:

Abstract Despite continual progress in the technologies and regimens for cancer therapy, the treatment outcome of fatal metastatic breast cancer is far from satisfactory. Encouragingly, nanotechnology has emerged as a valuable tool to optimize drug delivery process in cancer therapy via preventing the cargos from degradation, improving the tumor-targeting efficiency, enhancing therapeutic agents’ retention in specific sites, and controlling drug release. In the last decade, several mechanisms of suppressing tumor metastasis by functional nano drug delivery systems (NDDSs) have been revealed an

APA, Harvard, Vancouver, ISO, and other styles

30

Campbell, Kirsteen J., Susan M. Mason, Matthew L. Winder, et al. "Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function." Cell Death & Differentiation 28, no. 9 (2021): 2589–600. http://dx.doi.org/10.1038/s41418-021-00773-4.

Full text

Abstract:

AbstractHigh levels of the anti-apoptotic BCL-2 family member MCL-1 are frequently found in breast cancer and, appropriately, BH3-mimetic drugs that specifically target MCL-1’s function in apoptosis are in development as anti-cancer therapy. MCL-1 also has reported non-canonical roles that may be relevant in its tumour-promoting effect. Here we investigate the role of MCL-1 in clinically relevant breast cancer models and address whether the canonical role of MCL-1 in apoptosis, which can be targeted using BH3-mimetic drugs, is the major function for MCL-1 in breast cancer. We show that MCL-1 i

APA, Harvard, Vancouver, ISO, and other styles

31

Ren, Lili, Lirong Qiu, Binbin Huang, et al. "Preparation and Characterization of Anti-Cancer Crystal Drugs Based on Erythrocyte Membrane Nanoplatform." Nanomaterials 11, no. 10 (2021): 2513. http://dx.doi.org/10.3390/nano11102513.

Full text

Abstract:

The simple and functional modification of the nanoparticle’s surface is used to efficiently deliver chemotherapeutic drugs for anti-cancer treatment. Here, we construct a nanocrystalline drug delivery system with doxorubicin wrapped in red blood cell membranes for the treatment of mouse breast cancer models. Compared with traditional free drug treatments, the biodegradable natural red blood cell membrane is combined with pure crystalline drugs. The nanoparticles obtained by the preparation method have superior properties, such as good stability, significantly delaying the release of drugs and

APA, Harvard, Vancouver, ISO, and other styles

32

Samuel, Samson Mathews, Elizabeth Varghese, Lenka Koklesová, Alena Líšková, Peter Kubatka, and Dietrich Büsselberg. "Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells." Cancers 12, no. 9 (2020): 2482. http://dx.doi.org/10.3390/cancers12092482.

Full text

Abstract:

Despite the leaps and bounds in achieving success in the management and treatment of breast cancers through surgery, chemotherapy, and radiotherapy, breast cancer remains the most frequently occurring cancer in women and the most common cause of cancer-related deaths among women. Systemic therapeutic approaches, such as chemotherapy, although beneficial in treating and curing breast cancer subjects with localized breast tumors, tend to fail in metastatic cases of the disease due to (a) an acquired resistance to the chemotherapeutic drug and (b) the development of intrinsic resistance to therap

APA, Harvard, Vancouver, ISO, and other styles

33

Salako, Kehinde S. "Screening of Amodiaquine for its in vitro Anti-cancer Activity on Breast Cancer Cell Lines- a Case Study for Drug Reprofiling." Pan African Journal of Life Sciences 5, no. 2 (2021): 263–73. http://dx.doi.org/10.36108/pajols/1202.50.0240.

Full text

Abstract:

Background: Cancer is one of the foremost contributors to global disease bur den and constantly requires new therapeutic options. The development of new drugs has failed to keep up with its incidence. Hence, drug reprofiling strategies are emerging as novel therapeutic options. The study aimed to evaluate the anti-cancer activity of amodiaquine (anti-malarial drug) using a combination of murine and human breast cancer cell lines Methods: Amodiaquine was authenticated by ultra-violet spectrophotometry, high- performance liquid chromatography and 1D nuclear magnetic resonance. In vitro cytotoxic

APA, Harvard, Vancouver, ISO, and other styles

34

Gao, Min, Yuan Quan, Xiong-Hui Zhou, and Hong-Yu Zhang. "PheWAS-Based Systems Genetics Methods for Anti-Breast Cancer Drug Discovery." Genes 10, no. 2 (2019): 154. http://dx.doi.org/10.3390/genes10020154.

Full text

Abstract:

Breast cancer is a high-risk disease worldwide. For such complex diseases that are induced by multiple pathogenic genes, determining how to establish an effective drug discovery strategy is a challenge. In recent years, a large amount of genetic data has accumulated, particularly in the genome-wide identification of disorder genes. However, understanding how to use these data efficiently for pathogenesis elucidation and drug discovery is still a problem because the gene–disease links that are identified by high-throughput techniques such as phenome-wide association studies (PheWASs) are usuall

APA, Harvard, Vancouver, ISO, and other styles

35

Ciftci, Halilibrahim, Belgin Sever, Nusret Kaya, et al. "Studies on 1,4-Quinone Derivatives Exhibiting Anti-Leukemic Activity along with Anti-Colorectal and Anti-Breast Cancer Effects." Molecules 28, no. 1 (2022): 77. http://dx.doi.org/10.3390/molecules28010077.

Full text

Abstract:

Colorectal cancer (CRC), breast cancer, and chronic myeloid leukemia (CML) are life-threatening malignancies worldwide. Although potent therapeutic and screening strategies have been developed so far, these cancer types are still major public health problems. Therefore, the exploration of more potent and selective new agents is urgently required for the treatment of these cancers. Quinones represent one of the most important structures in anticancer drug discovery. We have previously identified a series of quinone-based compounds (ABQ-1-17) as anti-CML agents. In the current work, ABQ-3 was ta

APA, Harvard, Vancouver, ISO, and other styles

36

Guo, Ashley, Priyanka Rajan, Mohammed Alruwaili, et al. "Abstract P3-08-27: Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): P3–08–27—P3–08–27. https://doi.org/10.1158/1557-3265.sabcs24-p3-08-27.

Full text

Abstract:

Abstract Metastatic breast cancer (MBC) is a life-threatening disease with lowest 5-year survival rates in patients with metastatic triple-negative breast cancer (mTNBC). Most MBCs carry mutant p53 that drives cancer progression and metastasis in part by promoting the build-up of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), major immune suppressive cells in the immune environment. At present, there are no effective treatment options for p53-mutant BC, while existing chemotherapy-based treatments exhibit low selectivity for p53mut status and high frequency o

APA, Harvard, Vancouver, ISO, and other styles

37

Mughees, Mohd, Mohd Samim, Yadhu Sharma, and Saima Wajid. "Identification of protein targets and the mechanism of the cytotoxic action of Ipomoea turpethum extract loaded nanoparticles against breast cancer cells." Journal of Materials Chemistry B 7, no. 39 (2019): 6048–63. http://dx.doi.org/10.1039/c9tb00824a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Raju, Senthil Kumar, Shridharshini Kumar, Praveen Sekar, Naveena Sundhararajan, and Yogadharshini Nagalingam. "Ligand Based Multi-Targeted Molecular Docking Analysis o f Terpenoid Phytoconstituents as Potential Chemotherapeutic Agents Against Breast Cancer: An In Silico Approach." Journal of Pharmaceutical Research 22, no. 2 (2023): 55–62. http://dx.doi.org/10.18579/jopcr/v22.2.23.5.

Full text

Abstract:

Breast cancer is one of the most common cancers in women all around the world and is a dominant cause of deaths occurring all around the globe. The available potent drugs for breast cancer show adverse effects and resistance and are found to be ineffective in patients. The high cost of currently available cancer therapy and certain limitations of current treatment make it necessary to search for novel, cost-effective and efficient methods of cancer treatment. Phytochemicals are directly involved in treatment or precursors to synthesize useful drugs. Therefore, in the current investigation, 500

APA, Harvard, Vancouver, ISO, and other styles

39

Rho, Jong Kook, Gyeong Hee Lee, Seung Min Byun, et al. "Abstract 1801: Development and evaluation of KMD111: A HER2-targeted novel drug delivery system for gastric and breast cancer therapy." Cancer Research 85, no. 8_Supplement_1 (2025): 1801. https://doi.org/10.1158/1538-7445.am2025-1801.

Full text

Abstract:

Abstract Background: HER2-low expressing cancers, including gastric and breast cancers, have historically been categorized as HER2-negative, limiting targeted therapy options. To address this, we developed KMD111, a novel HER2-targeted drug delivery platform using mesoporous silica nanoparticles (MSNs) loaded with a potent anticancer drug and coated with HER2-targeting affibody proteins via a glutathione-sensitive GST-GSH bio-linker. KMD111 demonstrated high tumor-targeting efficiency, superior anti-tumor efficacy, and a favorable safety profile in preclinical models, providing stability in th

APA, Harvard, Vancouver, ISO, and other styles

40

Chen, Shuyi, Yabiao Gao, Ping Zhu, et al. "Anti-cancer Drug Anlotinib Promotes Autophagy and Apoptosis in Breast Cancer." Frontiers in Bioscience-Landmark 27, no. 4 (2022): 125. http://dx.doi.org/10.31083/j.fbl2704125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ahmed Alhayali, Ali Sami, Waseem Ali Hasan, and Firas Subhi Salah. "Autophagy induction using Resveratrol enhances the anti-cancer efficacy of Doxazosin in breast cancer cells." Sumer 4 8, CSS 4 (2023): 1–10. http://dx.doi.org/10.21931/rb/css/2023.08.04.88.

Full text

Abstract:

The combination of anti-cancer drugs improves effectiveness compared to the mono-therapy scenario by targeting key pathways synergistically or in an additive way. Doxazosin (DOX) and Resveratrol (RES) are reported to have an anti-cancer impact against different cancer cells. Aim: To evaluate the anti-cancer properties of Doxazosin and Resveratrol, each alone or in combination, in inhibiting breast cancer cell proliferation. Methods: MCF-7 cancer cells were seeded to a confluent monolayer and treated with 100, 50, 25, 12.5, 6.25, and 3.12 µM of each drug alone and as a combination. Cytotoxicity

APA, Harvard, Vancouver, ISO, and other styles

42

Chembukavu, Suraj Narayanan, and Andrew J. Lindsay. "Therapy-induced senescence in breast cancer: an overview." Exploration of Targeted Anti-tumor Therapy 5, no. 4 (2024): 902–20. http://dx.doi.org/10.37349/etat.2024.00254.

Full text

Abstract:

Outcomes for women with breast cancer have improved dramatically in recent decades. However, many patients present with intrinsic drug resistance and others are initially sensitive to anti-cancer drugs but acquire resistance during the course of their treatment, leading to recurrence and/or metastasis. Drug therapy-induced senescence (TIS) is a form of drug resistance characterised by the induction of cell cycle arrest and the emergence of a senescence-associated secretory phenotype (SASP) that can develop in response to chemo- and targeted- therapies. A wide range of anticancer interventions

APA, Harvard, Vancouver, ISO, and other styles

43

Park, Jinkyung, Dahee Jeong, Meeryoung Song, and Bonglee Kim. "Recent Advances in Anti-Metastatic Approaches of Herbal Medicines in 5 Major Cancers: From Traditional Medicine to Modern Drug Discovery." Antioxidants 10, no. 4 (2021): 527. http://dx.doi.org/10.3390/antiox10040527.

Full text

Abstract:

Metastasis is the main cause of cancer-related death. Despite its high fatality, a comprehensive study that covers anti-metastasis of herbal medicines has not yet been conducted. The aim of this study is to investigate and assess the anti-metastatic efficacies of herbal medicines in the five major cancers, including lung, colorectal, gastric, liver, and breast cancers. We collected articles published within five years using PubMed, Google Scholar, and Web of Science with “cancer metastasis” and “herbal medicine” as keywords. Correspondingly, 16 lung cancer, 23 colorectal cancer, 10 gastric can

APA, Harvard, Vancouver, ISO, and other styles

44

Li, Rui, Xiao Hu, Ning Ge, Michael Kerin, and Laura Barkley. "Abstract 3142: Patient-derived models of breast cancer for drug screening and precision medicine approaches." Cancer Research 85, no. 8_Supplement_1 (2025): 3142. https://doi.org/10.1158/1538-7445.am2025-3142.

Full text

Abstract:

Abstract Introduction: The breast tumor microenvironment (TME) consists of a complex and heterogeneous network of cancer cells, cancer-associated fibroblasts (CAFs), immune cells, and an acellular extracellular matrix (ECM). These components critically impact treatment responses, emphasizing the utilization of patient-derived models that closely mimic the TME. Such models provide valuable insights into chemotherapy responses and facilitate the development of personalized treatment strategies. Natural products represent a vast and diverse source for anti-tumor drug discovery due to their struct

APA, Harvard, Vancouver, ISO, and other styles

45

Barnard, Mollie E., Nuo N. Xu, Dennis Jones, and Julie R. Palmer. "Abstract B136: Hypertension, anti-hypertensive drug use, and breast cancer survival among Black women." Cancer Epidemiology, Biomarkers & Prevention 32, no. 12_Supplement (2023): B136. http://dx.doi.org/10.1158/1538-7755.disp23-b136.

Full text

Abstract:

Abstract Introduction: In the United States (US), Black women are 59% more likely to have hypertension than White women. US Black women are also 40% more likely to die from breast cancer when compared to US White women, yet the associations between hypertension, use of anti-hypertensive medications, and breast cancer survival are not well-established in this population. Methods: The prospective Black Women’s Health Study includes 1,757 women with invasive breast cancer diagnosed at stages 1, 2 or 3. Data on physician-diagnosed hypertension and use of anti-hypertensive medications (i.e., angiot

APA, Harvard, Vancouver, ISO, and other styles

46

Rinnerthaler, Gabriel, Simon Gampenrieder, and Richard Greil. "HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer." International Journal of Molecular Sciences 20, no. 5 (2019): 1115. http://dx.doi.org/10.3390/ijms20051115.

Full text

Abstract:

Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully. Next to monoclonal anti-HER2 antibodies and tyrosine kinase inhibitors, the antibody-drug conjugate T-DM1 is a pillar of targeted treatment of advanced HER2-positive breast cancers. Currently, several HER2 directed antibody-drug conjugates are under clinical investigation for HER2 amplified but also HER2 expressing but not amplified breast tumors.

APA, Harvard, Vancouver, ISO, and other styles

47

Zlotos, Darius P., Thales Kronenberger, and Stefan A. Laufer. "Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands." Pharmaceutics 15, no. 1 (2022): 67. http://dx.doi.org/10.3390/pharmaceutics15010067.

Full text

Abstract:

Hormone-dependent cancers, such as certain types of breast cancer are characterized by over-expression of estrogen receptors (ERs). Anticancer drug conjugates combining ER ligands with other classes of anticancer agents may not only benefit from dual action at both anti-cancer targets but also from selective delivery of cytotoxic agents to ER-positive tumor cells resulting in less toxicity and adverse effects. Moreover, they could also take advantage of overcoming resistance typical for anti-hormonal monotherapy such as tamoxifen. In this review, we discuss the design, structures and pharmacol

APA, Harvard, Vancouver, ISO, and other styles

48

Feng, Huili, Lixin He, Talha Umar, et al. "Synergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition." Current Issues in Molecular Biology 47, no. 6 (2025): 403. https://doi.org/10.3390/cimb47060403.

Full text

Abstract:

Ivermectin (IVM) is a macrolide antiparasitic drug, and Metformin (MET) is a biguanide oral hypoglycemic drug. Studies have shown that both of them have obvious anti-tumor effects, but there have been no reports on the combined treatment of Canine breast tumors. This report aimed to investigate the effectiveness and the possible mechanism of drug combination on Canine breast cancers. Mouse breast tumor cells (4T1) and canine breast tumor cells (CMT-1211) were, respectively, treated with IVM, MET, and their combination, and then cell viability was assessed. After that, transcriptomic analysis w

APA, Harvard, Vancouver, ISO, and other styles

49

Jeong, Hwa Yeon, Hyeri Kim, Myunghwa Lee, et al. "Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy." International Journal of Molecular Sciences 21, no. 24 (2020): 9764. http://dx.doi.org/10.3390/ijms21249764.

Full text

Abstract:

In this study, HER2 RNA aptamers were conjugated to mertansine (DM1) and the anti-cancer effectiveness of the conjugate was evaluated in HER2-overexpressing breast cancer models. The conjugate of HER2 aptamer and anticancer drug DM1 (aptamer-drug conjugate, ApDC) was prepared and analyzed using HPLC and mass spectrometry. The cell-binding affinity and cytotoxicity of the conjugate were determined using confocal microscopy and WST-1 assay. The in vivo anti-tumoral efficacy of ApDC was also evaluated in mice carrying BT-474 breast tumors overexpressing HER2. The synthesized HER2-specific RNA apt

APA, Harvard, Vancouver, ISO, and other styles

50

"A Statistical Study on Anti-Breast Cancer Drug Screening." Journal of Pharmaceutical Research 7, no. 1 (2022). http://dx.doi.org/10.33140/jpr.07.01.01.

Full text

Abstract:

Breast cancer is one of the most lethal cancers, estrogen receptor α Subtype (ERα) is an important target. The compounds that able to fight ERα active may be candidates for treatment of breast cancer. The drug discovery process is a very large and complex process that often requires one selected from a large number of compounds. This paper considers the independence, coupling, and relevance of bioactivity descriptors, selects the 15 most potentially valuable bioactivity descriptors from 729 bioactivity descriptors. An optimized back propagation neural network is used for ERα, the pharmacokinet

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!